[go: up one dir, main page]

PE20091673A1 - NEW CARBAZOLE DERIVATIVES, HSP90 INHIBITORS, COMPOSITIONS CONTAINING THEM AND USE - Google Patents

NEW CARBAZOLE DERIVATIVES, HSP90 INHIBITORS, COMPOSITIONS CONTAINING THEM AND USE

Info

Publication number
PE20091673A1
PE20091673A1 PE2009000368A PE2009000368A PE20091673A1 PE 20091673 A1 PE20091673 A1 PE 20091673A1 PE 2009000368 A PE2009000368 A PE 2009000368A PE 2009000368 A PE2009000368 A PE 2009000368A PE 20091673 A1 PE20091673 A1 PE 20091673A1
Authority
PE
Peru
Prior art keywords
benzamide
compositions containing
carbazol
benzimidazol
hydroxy
Prior art date
Application number
PE2009000368A
Other languages
Spanish (es)
Inventor
Marcel Alasia
Luc Bertin
Victor Certal
Franck Halley
Patrick Mailliet
Herve Minoux
Jean-Marie Ruxer
Perez Maria Mendez
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091673(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20091673A1 publication Critical patent/PE20091673A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE HET ES DE PREFERENCIA BENZIMIDAZOL-2-IL, BENZOPIRIDIN-3-IL, TIAZOL-2-IL, ENTRE OTROS; R ES 2-(4-HIDROXI-CICLOHEXILAMINO)BENZAMIDA, 2-AMINO-BENZAMIDA, 1-ETANOL-3-AMINO-BENZOISOXAZOL, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-[4-(6-FLUORO-1H-BENZIMIDAZOL-2-IL)-9H-CARBAZOL-9-IL]-2-(4-TRANS-HIDROXI-CICLOHEXILAMINO)-BENZAMIDA; 2-(DIETILAMINO-ETILAMINO)-4-[4-(6-FLUORO-1H-BENZIMIDAZOL-2-IL)-9H-CARBAZOL-9-IL]-BENZAMIDA; 3-(TRANS-4-HIDROXI-CILOHEXILAMINO)-5-[(4-QUINOLEIN-3-IL)-9H-CARBAZOL-9-IL]-PIRIDIN-2-CARBOXAMIDA; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA CHAPERONA HSP90 (PROTEINA DE CHOQUE TERMICO) UTILES EN EL TRATAMIENTO DE TUMORES MALIGNOSREFERS TO A COMPOUND OF FORMULA I, WHERE HET BENZIMIDAZOL-2-IL, BENZOPIRIDIN-3-IL, THIAZOL-2-IL, AMONG OTHERS, IS PREFERRED; R IS 2- (4-HYDROXY-CYCLOHEXYLAMINE) BENZAMIDE, 2-AMINO-BENZAMIDE, 1-ETHANOL-3-AMINO-BENZOISOXAZOLE, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: 4- [4- (6-FLUORO-1H-BENZIMIDAZOL-2-IL) -9H-CARBAZOL-9-IL] -2- (4-TRANS-HYDROXY-CYCLOHEXYLAMINE) -BENZAMIDE; 2- (DIETHYLAMINE-ETHYLAMINE) -4- [4- (6-FLUORO-1H-BENZIMIDAZOL-2-IL) -9H-CARBAZOL-9-IL] -BENZAMIDE; 3- (TRANS-4-HYDROXY-CYLOHEXYLAMINE) -5 - [(4-QUINOLEIN-3-IL) -9H-CARBAZOL-9-IL] -PYRIDIN-2-CARBOXAMIDE; AMONG OTHERS. SAID COMPOUNDS ARE INHIBITORS OF THE PROTEIN CHAPERONE HSP90 (HEAT SHOCK PROTEIN) USEFUL IN THE TREATMENT OF MALIGNANT TUMORS

PE2009000368A 2008-03-14 2009-03-12 NEW CARBAZOLE DERIVATIVES, HSP90 INHIBITORS, COMPOSITIONS CONTAINING THEM AND USE PE20091673A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801394A FR2928645A1 (en) 2008-03-14 2008-03-14 NOVEL CARBAZOLE DERIVATIVES INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME AND USE THEREOF

Publications (1)

Publication Number Publication Date
PE20091673A1 true PE20091673A1 (en) 2009-11-14

Family

ID=39930567

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000368A PE20091673A1 (en) 2008-03-14 2009-03-12 NEW CARBAZOLE DERIVATIVES, HSP90 INHIBITORS, COMPOSITIONS CONTAINING THEM AND USE

Country Status (24)

Country Link
US (1) US8309721B2 (en)
EP (1) EP2265598A2 (en)
JP (1) JP5674483B2 (en)
KR (1) KR20100130603A (en)
CN (1) CN102026992A (en)
AR (1) AR070836A1 (en)
AU (1) AU2009232121A1 (en)
BR (1) BRPI0909731A2 (en)
CA (1) CA2718488A1 (en)
CL (1) CL2009000619A1 (en)
CO (1) CO6251295A2 (en)
CR (1) CR11653A (en)
DO (1) DOP2010000272A (en)
EA (1) EA201071078A1 (en)
EC (1) ECSP10010473A (en)
FR (1) FR2928645A1 (en)
IL (1) IL208059A0 (en)
MA (1) MA32206B1 (en)
MX (1) MX2010010018A (en)
NI (1) NI201000150A (en)
PE (1) PE20091673A1 (en)
TW (1) TW200938541A (en)
UY (1) UY31711A (en)
WO (1) WO2009122034A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035416A1 (en) * 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Hsp90 modulating compounds, compositions, methods and uses
KR20140025327A (en) * 2011-01-07 2014-03-04 다이호야쿠힌고교 가부시키가이샤 Novel bicyclic compound or salt thereof
BR112013017416A2 (en) 2011-01-07 2019-09-24 Taiho Pharmaceutical Co Ltd derived from indole or indazole or salt thereof
JP5842630B2 (en) 2011-03-16 2016-01-13 株式会社リコー Carbazole derivatives and semiconductor nanocrystals
JP2014075556A (en) * 2012-10-05 2014-04-24 Idemitsu Kosan Co Ltd Organic electroluminescent element material and organic electroluminescent element using the same
CN104903308B (en) * 2013-01-10 2018-06-08 默克专利股份有限公司 Piperidyl carbazoles as antimalarial
EP3059225A4 (en) 2013-10-17 2017-09-06 Shionogi & Co., Ltd. Novel alkylene derivative
KR20160093675A (en) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 Inhibitors of bruton's tyrosine kinase
WO2016008010A1 (en) * 2014-07-16 2016-01-21 Novogen ltd Functionalised and substituted carbazoles as anti-cancer agents
KR102478309B1 (en) * 2014-10-01 2022-12-15 얀센 파마슈티칼즈, 인코포레이티드 Mono- or di-substituted indoles as dengue viral replication inhibitors
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
CA2984153A1 (en) * 2015-04-29 2016-11-03 Arena Pharmaceuticals, Inc. 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
JOP20160086B1 (en) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JO3633B1 (en) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever
JOP20160198B1 (en) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever
DE102016122122B4 (en) * 2015-11-18 2021-02-11 Cynora Gmbh Organic molecules, in particular for use in organic optoelectronic devices
US9966542B2 (en) * 2016-06-02 2018-05-08 E I Du Pont De Nemours And Company Electroactive materials
DE102017008073A1 (en) * 2017-08-28 2019-02-28 Henkel Ag & Co. Kgaa New anionic surfactants and detergents and cleaners containing them
CN111217741B (en) * 2019-03-01 2022-03-15 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Fluorine-substituted monocarbazole derivatives, preparation method and application thereof
CN118834213A (en) * 2022-04-28 2024-10-25 北京丹擎医药科技有限公司 Tricyclic heterocyclic derivative, composition and application thereof
WO2024199444A1 (en) * 2023-03-31 2024-10-03 上海翊维康医药有限责任公司 Heteroaromatic ring compound, preparation method therefor, and use thereof
CN117159570B (en) * 2023-11-01 2024-01-23 云南中医药大学 Application of 6-acyloxymannose azide derivatives in combination with fluconazole in the preparation of drugs against drug-resistant Candida albicans
CN117486782A (en) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 N-substituted carbazole derivative and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317926B1 (en) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti TRICYCLIC DERIVATIVES OF INDOLE FOR ANTIANGIOGENIC ACTIVITY.
EP2298748B1 (en) * 2004-11-18 2016-07-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
EP1924557A2 (en) * 2005-09-16 2008-05-28 Serenex, Inc. Carbazole derivatives
US8405508B2 (en) 2006-08-09 2013-03-26 Emd Millipore Corporation Use of gamma hardened RFID tags in pharmaceutical devices

Also Published As

Publication number Publication date
CN102026992A (en) 2011-04-20
IL208059A0 (en) 2010-12-30
CA2718488A1 (en) 2009-10-08
CL2009000619A1 (en) 2011-02-18
JP5674483B2 (en) 2015-02-25
EA201071078A1 (en) 2011-04-29
MA32206B1 (en) 2011-04-01
US8309721B2 (en) 2012-11-13
CO6251295A2 (en) 2011-02-21
WO2009122034A3 (en) 2009-12-03
MX2010010018A (en) 2010-12-15
KR20100130603A (en) 2010-12-13
UY31711A (en) 2009-11-10
NI201000150A (en) 2011-03-29
US20110166169A1 (en) 2011-07-07
TW200938541A (en) 2009-09-16
AR070836A1 (en) 2010-05-05
WO2009122034A2 (en) 2009-10-08
EP2265598A2 (en) 2010-12-29
JP2011513473A (en) 2011-04-28
CR11653A (en) 2010-11-22
FR2928645A1 (en) 2009-09-18
DOP2010000272A (en) 2010-10-15
ECSP10010473A (en) 2010-10-30
BRPI0909731A2 (en) 2019-03-06
AU2009232121A1 (en) 2009-10-08
WO2009122034A8 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
PE20091673A1 (en) NEW CARBAZOLE DERIVATIVES, HSP90 INHIBITORS, COMPOSITIONS CONTAINING THEM AND USE
RU2454415C9 (en) Indole derivative
PE20141375A1 (en) GLUCOKINASE ACTIVATORS
PE20030547A1 (en) IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF OBESITY
PE20140913A1 (en) NAMPT AND ROCK INHIBITORS
PE20091952A1 (en) TIAZOLE AND OXAZOLE COMPOUNDS OF BENZENE SULFONAMIDE
PE20120812A1 (en) VINYL INDAZOLYL COMPOUNDS
PE20090601A1 (en) PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS
CR11483A (en) PEPTIDE INHIBITORS DESFORMILASA
EA201000562A1 (en) DERIVATIVES N- (PYRAZOL-3-IL) BENZAMIDE AS ACTIVATORS GLUKOKINAZES
EA200901514A1 (en) NEW SOLVATIVE AND CRYSTAL FORM OF CARBAMOILCYCLOGEXAN DERIVATIVES
PE20091656A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAF KINASE
CL2016001023A1 (en) Compound n- (1- (4- (2- (4-chloro-2,6-dimethylpyrimidin-5-yl) ethyl) piperidin-1-yl) -1-oxopropan-2-yl) cyclopropanecarboxamide, stereoisomer, inhibitors ghrelin o-acyltransferase (goat); pharmaceutical composition; and use to reduce weight gain and to treat type 2 diabetes.
PE20161342A1 (en) COMBINATIONS OF HISTONE DESACETILASE INHIBITORS AND IMMUNOMODULATING DRUGS
PE20090434A1 (en) SULFONIL AMIDE DERIVATIVES AS KINASE INHIBITORS
NZ590268A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AR057109A1 (en) BENZIMIDAZOLS REPLACED AND METHODS TO USE THEM AS INHIBITORS OF KINASES ASSOCIATED WITH TUMORIGENESIS
PE20141700A1 (en) 2- (2,4,5-ANILINE SUBSTITUTED) PYRIMIDINE COMPOUNDS
UA111725C2 (en) CRYSTAL (R) - (E) -2- (4- (2- (5- (1- (3,5-Dichloropyridin-4-yl) ethoxy) -1H-indazol-3-yl) vinyl) -1H- PYRAZOL-1-IL) ETHANOL
CY1117593T1 (en) CGRP COMPETITOR-RECEPTOR
CO6260074A2 (en) COMPOUNDS OF 5- (4- (HALO-ALCOXI) -PENYL) -PIRIMIDIN-2-AMINA AND COMPOSITIONS AS KINASE INHIBITORS
AR053569A1 (en) PIRAZOL DERIVATIVES
PE20120655A1 (en) TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINES ACTIVATED BY MITOGEN P38 (MAP)
PE20050229A1 (en) DERIVATIVES OF ETHINYLPROLINE
PE20091243A1 (en) FUSED HETEROCYCLIC COMPOUND

Legal Events

Date Code Title Description
FD Application declared void or lapsed